Status:
WITHDRAWN
Patients Who Receive 131 I-MIBG
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Brain and Nervous System
Eligibility:
All Genders
1-30 years
Brief Summary
This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. ...
Detailed Description
This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subject must meet all of the following applicable inclusion criteria to participate in this study:
- Written informed consent, and assent where applicable, and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- Age greater than or equal to 1 years and less than or equal to 30 years at the time of therapy.
- Subject is scheduled to receive 131 I-MIBG therapy.
- Diagnosis of refractory, progressive or relapsed Neuroblastoma, Malignant Paraganglioma, Malignant Pheochromocytoma or other Neuroendocrine Tumors.
- As determined by the enrolling physician, ability of the subject and parent/caregiver to understand and comply with study procedures for the entire length of the study.
- Exclusion Criteria
- Subjects meeting the criteria below may not participate in the study:
- 1\. Prior enrollment on LCI-PED-NEU-MIBG-001 trial.
Exclusion
Key Trial Info
Start Date :
March 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04770831
Start Date
March 10 2021
End Date
December 1 2024
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204